市場調查報告書
商品編碼
1335881
數位劑量吸入器的全球市場規模、佔有率和行業趨勢分析報告:按產品(計量吸入器(MDI)、乾粉吸入器(DPI))、按類型、按適應症(慢性阻塞性肺病、氣喘等)、地區預測,2023-2030Global Digital Dose Inhaler Market Size, Share & Industry Trends Analysis Report By Product (Metered Dose Inhaler (MDI), and Dry Powder Inhaler (DPI)), By Type, By Indication (COPD, Asthma, and Others), By Regional Outlook and Forecast, 2023 - 2030 |
預計到 2030 年,數位劑量吸入器市場規模將達到 490 億美元,預測期內年複合成長率為 19.6%。
此外,為感染者提供護理的醫療用品的需求也在增加。呼吸支援設備,如霧化器、制氧機、維生器和監視器是初級保健中最常用的醫療設備。 COVID-19大流行的持續爆發對醫療設備產業產生了積極影響。它影響了數位劑量吸入市場。然而,這種流行病的蔓延影響了供應鏈並減少了對數位劑量吸入設備的需求,導致許多地區的工業暫時停工和政府宣布封鎖。
此外,由於對患者資料安全性的擔憂,市場擴張預計將緩慢。由於缺乏對慢性阻塞性肺病和氣喘症狀的了解,大多數患有呼吸道疾病的人未能得到診斷,因此接受了不正確的治療。這可能是由於患者缺乏技術熟悉度和支付限制造成的。鑑於目前的情況,有限的設備可用性也是一個問題,將對預測期內的數位劑量吸入器市場產生負面影響。
產品展望
根據產品,市場分為計量吸入器(MDI)和乾粉吸入器(DPI)。 2022年,計量吸入器(MDI)領域佔市場最高收入佔有率。這是由於醫療費用上漲和呼吸系統疾病患者數量增加。此外,與吸入藥物開拓相關的持續技術進步,藥物動力學/藥效學(PK/PD)建模和以小劑量輸送高劑量藥物的基於奈米技術的製劑,提高了藥物的治療效果.增加和影響整個市場的關鍵要素。
按類型分類的展望
按類型分類,市場分為品牌藥和學名藥。學名藥領域在市場上佔有最高的收入佔有率。數位吸入器通常包括感測器和連接裝置,用於監控和追蹤藥物使用。數位吸入器可以記錄吸入器使用的日期、時間和頻率,為患者、醫療保健提供者和研究人員提供有價值的資訊。一些數位吸入器可以透過藥物提醒和警報進行編程。
指標展望
根據跡象,市場分為氣喘、慢性阻塞性肺病(COPD)等。 2022年,慢性阻塞性肺病(COPD)細分市場佔據主導地位。由於全球慢性阻塞性肺病罹患率上升,預計該細分市場將在預測期內佔據主導地位。菸草使用、空氣污染、花粉、化學蒸氣和兒童感染疾病都會導致慢性阻塞性肺病。數位劑量吸入器可以幫助慢性阻塞性肺病患者監測他們的呼吸健康和藥物依從性,使他們能夠更有效地管理他們的疾病。
區域展望
按地區分類,對北美、歐洲、亞太地區和拉丁美洲地區市場進行了分析。 2022年,北美地區以最高的收入佔有率引領市場。這是由於密集的研究和開發工作以及對目前可用高科技呼吸器的認知的提高。此外,兒童和老年人呼吸道疾病盛行率的增加將推動預測期內市場的擴張。
The Global Digital Dose Inhaler Market size is expected to reach $49 billion by 2030, rising at a market growth of 19.6% CAGR during the forecast period.
Cigarette smoking and long-term exposure to other respiratory contaminants are typically the cause of various diseases, including asthma. The asthma segment will capture more than 30% share of the market by 2030. The World Health Organization (WHO) estimates that annually, tobacco kills more than eight million people. 7 million deaths are due to direct tobacco use, while approximately 1.2 million are due to latent or secondhand smoking. Cigarette smoking is one of the most prevalent forms of tobacco use worldwide. Over 80% of the 1.3 billion tobacco consumers reside in low- and middle-income countries, where mortality and illness due to tobacco use are prevalent. Some of the factors impacting the market are globally increasing air pollution, developing technological advances and concerns related to patient data security.
Automobiles, forest fires, household combustion, and industrial facilities are widely recognized sources of air pollution. Particulate matter, ozone, carbon monoxide, sulfur dioxide, and nitrogen are the pollutants of most threat to public health. Both indoor and external air pollution contribute significantly to mortality and morbidity by causing respiratory and other diseases. According to the World Health Organization, nearly all the world's population consumes air with elevated levels of pollutants exceeding WHO guidelines. Low- and middle-income countries are the most vulnerable to these threats. Additionally, the increasing adoption of AI and IoT has been identified as one of the most significant market trends. AI technology analyzes intricate medical data using algorithms and software, reducing the need for direct human input. This will aid in decreasing the likelihood of human error, reducing treatment costs, and enhancing healthcare outcomes. Therefore, Long-term exposure to ambient air contaminants is associated with an increase in the incidence of respiratory diseases and the increasing incorporation of AI and the adoption of IoT will improve the treatment of asthma and COPD, thereby increasing demand.
Furthermore, in order to provide care for the infected population, there is a growing demand for medical supplies. Respiratory support devices like atomizers, oxygen generators, life-support machines, and monitors are some of the most frequently utilized medical devices in primary medical care. The continuous outbreak of the COVID-19 pandemic had a positive effect on the medical device industry. It affects the market for digital dose inhalation. However, this escalating pandemic affects the supply chain and reduces demand for digital dose inhalation devices, resulting in the temporary shutdown of industries and the announcement of lockdowns by governments in numerous regions.
Additionally, due to concerns about patient data security, it is predicted that the market will expand slowly. Due to a lack of knowledge of the symptoms of COPD and asthma, the vast majority of individuals with respiratory illnesses go undiagnosed and are consequently given the incorrect treatment. This may be a result of patients not being technologically savvy and the payment restrictions. The device's limited availability is another issue that, given the existing circumstance, will have a negative impact on the market for digital dosage inhalers throughout the projection period.
Product Outlook
Based on Product, the market is segmented into metered dose inhaler (MDI) and dry powder inhaler (DPI). In 2022, the metered dose inhaler (MDI) segment held the highest revenue share in the market. This is due to rising healthcare costs and increased respiratory disease cases. Furthermore, consistent technological advancements related to the development of inhalation medication, like mechanistic Pharmacokinetic/Pharmacodynamics (PK/PD) modeling, and nanotechnology-based formulations with high drug loads delivered in smaller dose sizes, are some of the critical factors involved in enhancing the therapeutic efficacy of the medication and influencing the overall market.
Type Outlook
On the basis of type, the market is fragmented into branded medication and generic medication. The generic medication segment garnered the highest revenue share in the market. Frequently, digital inhalers include sensors and connectivity features that monitor and track medication usage. They can log the date, time, and frequency of inhaler use, providing valuable information to patients, healthcare providers, and researchers. A few digital inhalers can be programmed with medication reminders and alerts.
Indication Outlook
By indication, the market is bifurcated into asthma, chronic obstructive pulmonary disease (COPD), and others. In 2022, the chronic obstructive pulmonary disease (COPD) segment dominated the market. The segment is anticipated to dominate over the forecast period due to the global increase in COPD incidence. Tobacco use, air pollution, pollen, chemical vapors, and childhood infections are all causes of COPD. Digital Dose Inhalers aid COPD patients in monitoring their respiratory health and drug adherence, enabling them to manage their illness more effectively.
Regional Outlook
Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. In 2022, the North America region led the market by generating the highest revenue share. This is due to rigorous research and development efforts, as well as an increased awareness of the high-tech respiratory devices currently available. In addition, an increase in the prevalence of respiratory conditions among children and older people will drive market expansion over the forecast period.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Sensirion AG, Teva Pharmaceuticals Industries Ltd., OPKO Health, Inc., Propeller Health (ResMed, Inc.), Novartis AG, AstraZeneca PLC, Glenmark Pharmaceuticals Limited, Beximco Pharmaceuticals Ltd., GlaxoSmithKline PLC and Mundipharma Deutschland GmbH & Co. KG.
Strategies Deployed in Digital Dose Inhaler Market
Jun-2023: Teva Pharmaceutical signed an agreement with Phil, Inc., a patient access platform company. Under this agreement, both companies would make Digihaler products available for prescription utilizing the PhilRx Patient Access Platform. The Digihaler system offered by Teva is a smart inhaler that delivers objective inhaler data to support doctors and patients in asthma management.
Jan-2023: AstraZeneca received FDA approval for Airsupra, a pressurized metered-dose inhaler. The approval in the US is for the as-required treatment or prevention of bronchoconstriction and to decrease the risk of exacerbations in people suffering from Asthma of 18 years or more.
Jun-2022: Glenmark Pharm announced the launch of Indament, a novel fixed-dose combination (FDC) drug. The launched drug would be available in three forms with a fixed dose of Indacaterol 150 mcg and variable doses of Mometasone 80 mcg, 160 mcg and 320 mcg to be taken once daily.
Apr-2022: GlaxoSmithKline Pharmaceuticals rolled out Trelegy Ellipta, the first once-daily single-inhaler triple therapy, for Chronic Obstructive Pulmonary Disease patients. The product is used as a maintenance treatment to avert and relieve symptoms related to Chronic Obstructive Pulmonary Disease for patients of age 18 and above.
Sep-2020: Teva Respiratory, LLC., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., introduced AirDuo Digihaler inhalation powder and ArmonAir Digihaler inhalation powder, the digital maintenance inhalers for patients with asthma. The AirDuo Digiinhaler is utilized to manage symptoms of wheezing in patients and asthma. The ArmonAir Digihaler for the treatment of asthma in patients.
Jul-2020: Teva Respiratory, LLC., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. released ProAir Digihaler Inhalation Powder, the digital rescue inhaler indicated in patients of four years and above. The product is used for the prevention and treatment of bronchospasm who have reversible obstructive airway disease.
Jul-2020: Novartis received approval from European commision for Enerzair® Breezhaler®, including the sensor and app. The Product offers inhalation confirmation, medication reminders, and access to objective data to better help therapeutic decisions.
May-2020: Glenmark Pharmaceuticals Ltd. introduced AIRZ-FF, a Single Inhaler Triple Therapy. The launched product is for Chronic Obstructive Pulmonary Disease with the combination of two bronchodilators, Glycopyrronium & Formoterol, and the inhalation corticosteroid Fluticasone propionate. Furthermore, the AIRZ-FF decreases the risk of Severe attacks and eliminates dependence on multiple inhalers.
May-2020: Propeller Health came into partnership with AstraZeneca, a global pharmaceutical company. This partnership would offer respiratory patients a tool to help control their condition and enhance their medication adherence, a key factor in keeping people out of the hospital. Moreover, Propeller Health got FDA approval for a sensor and app to be used with AstraZeneca's Symbicort inhaler for asthma and COPD.
Market Segments covered in the Report:
By Product
By Type
By Indication
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures